Press Releases

Chief Medical Officer to present at the World Anti-Microbial Resistance Congress

By August 26, 2016No Comments

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that Dr. David Huang, Chief Medical Officer, will lead a panel discussion at the World Anti-Microbial Resistance Congress in Washington, USA on 9 September 2016.

The discussion is titled: ‘In-licensing: Addressing the deficiencies in the original development program to develop a unique non-combination anti-infective’

For further information on the conference please see:

Company Contacts

Motif Bio plc

Graham Lumsden, Chief Executive Officer
[email protected]

Walbrook PR Ltd. (Public and Investor Relations)

Paul McManus / Mike Wort
Main: +44 (0)20 7933 8780
Paul: +44 (0)7980 541 893
Mike: +44 (0)7900 608 002
[email protected]

About Motif Bio

About Motif Bio

Motif Bio plc is a clinical stage biopharmaceutical company engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), infections which are often caused by MRSA. We are currently enrolling and dosing patients in two global Phase 3 clinical trials with an IV formulation of iclaprim, for the treatment of ABSSSI.